John Cumbers

Last updated
John Cumbers
JohnCumbers.JPG
Born1979 (age 4344)
Alma mater Brown University, University of Edinburgh, University of Hull
Known for synthetic biology, investing, biostrategy, space settlement
AwardsNational Academies Keck Futures Initiative in 2010
Scientific career
Fields Molecular Biology, Cell Biology, Biochemistry, Synthetic Biology
InstitutionsSynBioBeta, NASA

John Robert Cumbers (born 1979) is a British molecular biologist living in the San Francisco Bay Area. He is founder and chief executive officer of SynBioBeta which promotes synthetic biology to build a more sustainable universe. [1] He founded BetaSpace, a space settlement innovation network aimed at sustaining human life on and off our planet and is an operating partner at DCVC, a firm in Silicon Valley focused on investments in biotechnology. [2]

Contents

Education and early life

John Cumbers was born on October 5, 1979, in Watford, Hertfordshire, Eastern England, 15 miles north-west of London. Since childhood, he showed a keen interest in biology and information technology. Cumbers attended Queens' School in Bushey, Hertfordshire for high school. In 2004, he obtained his BSc in Computer Science with Information Engineering at the University of Hull, a public research university in Kingston upon Hull, Yorkshire. For his master's in science and bioinformatics, he studied at the University of Edinburgh in Scotland. He obtained his PhD in molecular biology, Cell Biology and Biochemistry at Brown University, under the supervision of Lynn J. Rothschild at NASA Ames Research Center where they initiated a program in space synthetic biology for NASA. [3]

Career

After obtaining his doctorate, Cumbers served as lead for the Planetary Sustainability Initiative of the National Aeronautics and Space Administration (NASA), [4] the US federal agency responsible for aerospace research, aeronautics and the civilian space program. Between 2008 and 2015, Cumbers worked at the NASA Ames Research Center as a student and then contractor bioengineer and co-organized the first workshop on the applications of synthetic biology for space exploration. [5] He spent seven years in NASA's synthetic biology program, engineering organisms to provide food, fuel, medicine and other support materials for space missions [6] as well as mission design for space resource utilization, terraforming asteroids and life support.

In 2012, Cumbers founded SynBioBeta, a network for biological engineers, innovators and entrepreneurs who use biology to build a better and more sustainable universe. [7] [8] SynBioBeta hosts the Global Synthetic Biology Summit in San Francisco, California, every October. The Summit showcases the developments in synthetic biology that are transforming how people fuel, heal and feed the world. [9] [10] In addition to the Summit, SynBioBeta hosts a podcast and weekly digest.

In 2018, Cumbers founded BetaSpace, an innovation ecosystem investigating an off-Earth planet future. BetaSpace is focused on the broad areas of food and agriculture; water and waste; energy; and habitat and materials. [11] [12]

In 2017, Cumbers joined the Silicon Valley investment firm Data Collective (DCVC), a venture capital fund that backs entrepreneurs applying deep tech to transform giant industries. [13]

Publications

Cumbers is the author, with Karl Schmieder, of What’s Your Bio-Strategy? How to Prepare Your Business for Synthetic Biology [14] [15]

Cumbers has written on aging and insulin signalling, [16] the characterization of biological parts, [17] resource utilization on space missions, [18] synthetic biology in space, [19] [20] extremophiles (cyanobacteria and tardigrades) [21] and the impact of space resources on financial markets. [22] He is a regular contributor to Forbes.com, [23] writing on the impact of synthetic biology on manufacturing industries [24]

Awards and achievements

In 2010, Cumbers received the National Academies Keck Futures Initiative Award for his work in using synthetic biology in NASA's missions. [25]

Related Research Articles

<span class="mw-page-title-main">Astrobiology</span> Science concerned with life in the universe

Astrobiology is a scientific field within the life and environmental sciences that studies the origins, early evolution, distribution, and future of life in the universe by investigating its deterministic conditions and contingent events. As a discipline, astrobiology is founded on the premise that life may exist beyond Earth.

<span class="mw-page-title-main">Terraforming</span> Hypothetical planetary engineering process

Terraforming or terraformation ("Earth-shaping") is the hypothetical process of deliberately modifying the atmosphere, temperature, surface topography or ecology of a planet, moon, or other body to be similar to the environment of Earth to make it habitable for humans to live on.

<span class="mw-page-title-main">Synthetic biology</span> Interdisciplinary branch of biology and engineering

Synthetic biology (SynBio) is a multidisciplinary field of science that focuses on living systems and organisms, and it applies engineering principles to develop new biological parts, devices, and systems or to redesign existing systems found in nature.

<span class="mw-page-title-main">George Church (geneticist)</span> American geneticist

George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard. Through his Harvard lab Church has co-founded around 50 biotech companies pushing the boundaries of innovation in the world of life sciences and making his lab as a hotbed of biotech startup activity in Boston. In 2018, the Church lab at Harvard made a record by spinning off 16 biotech companies in one year. The Church lab works on research projects that are distributed in diverse areas of modern biology like developmental biology, neurobiology, info processing, medical genetics, genomics, gene therapy, diagnostics, chemistry & bioengineering, space biology & space genetics, and ecosystem. Research and technology developments at the Church lab have impacted or made direct contributions to nearly all "next-generation sequencing (NGS)" methods and companies. In 2017, Time magazine listed him in Time 100, the list of 100 most influential people in the world. In 2022, he was featured among the most influential people in biopharma by Fierce Pharma, and was listed among the top 8 famous geneticists of all time in human history. As of January 2023, Church serves as a member of the Bulletin of the Atomic Scientists' Board of Sponsors, established by Albert Einstein.

<span class="mw-page-title-main">Bioeconomy</span> Economic activity focused on biotechnology

Biobased economy, bioeconomy or biotechonomy is economic activity involving the use of biotechnology and biomass in the production of goods, services, or energy. The terms are widely used by regional development agencies, national and international organizations, and biotechnology companies. They are closely linked to the evolution of the biotechnology industry and the capacity to study, understand, and manipulate genetic material that has been possible due to scientific research and technological development. This includes the application of scientific and technological developments to agriculture, health, chemical, and energy industries.

<span class="mw-page-title-main">Christopher Voigt</span>

Christopher Voigt is an American synthetic biologist, molecular biophysicist, and engineer.

<span class="mw-page-title-main">Methuselah Foundation</span> U.S. nonprofit organization

The Methuselah Foundation is an American-based global non-profit organization based in Springfield, Virginia, with a declared mission to "make 90 the new 50 by 2030" by supporting tissue engineering and regenerative medicine therapies. The organization was originally incorporated by David Gobel in 2001 as the Performance Prize Society, a name inspired by the British governments Longitude Act, which offered monetary rewards for anyone who could devise a portable, practical solution for determining a ship's longitude.

<span class="mw-page-title-main">NASA Research Park</span> Research park near San Jose, California

NASA Research Park is a research park operated by NASA near San Jose, California which is developing a shared-use research and development campus in association with government entities, academia, industry and nonprofit organizations. NASA Research Park was approved by NASA in the fall of 2002 and has been active since then.

<span class="mw-page-title-main">Tardigrade</span> Phylum of microscopic animals, also known as water bears

Tardigrades, known colloquially as water bears or moss piglets, are a phylum of eight-legged segmented micro-animals. They were first described by the German zoologist Johann August Ephraim Goeze in 1773, who called them Kleiner Wasserbär. In 1777, the Italian biologist Lazzaro Spallanzani named them Tardigrada, which means "slow steppers".

Wendell Lim is an American biochemist who is the Byer's Distinguished Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco. He is the director of the UCSF Cell Design Institute. He earned his A.B. in chemistry from Harvard University working with Jeremy Knowles on enzyme evolutionary optimization. He obtained his Ph.D in biochemistry and biophysics from Massachusetts Institute of Technology under the guidance of Bob Sauer using genetic and biophysical approaches to understand the role of hydrophobic core interactions in protein folding. He then did his postdoctoral work with Frederic Richards at Yale University on the structure of protein interaction domains. Lim's work has focused on cell signaling, synthetic biology, and cell engineering, particularly in immune cells.

Jacob Cohen is a scientist at NASA Ames Research Center. He is Chief Scientist for the International Space Station (ISS) Utilization Office, the Deputy Division Chief (Acting) for the Mission Design Division and the Director of the Ames Biology Office within the Engineering Directorate at the Ames Research Center. He is also responsible for implementing new biology-based opportunities.

Synthetic virology is a branch of virology engaged in the study and engineering of synthetic man-made viruses. It is a multidisciplinary research field at the intersection of virology, synthetic biology, computational biology, and DNA nanotechnology, from which it borrows and integrates its concepts and methodologies. There is a wide range of applications for synthetic viral technology such as medical treatments, investigative tools, and reviving organisms.

ATUM is an American biotechnology company which provides tools for the life sciences, from design and synthesis of optimized DNA to protein production and GMP cell line development.

<span class="mw-page-title-main">Christina Smolke</span> American biologist

Christina Smolke is an American synthetic biologist whose primary research is in the use of yeast to produce opioids for medical use. She is a Full Professor of Bioengineering and of Chemical Engineering at Stanford University. She is the editor of The metabolic pathway engineering handbook (2010). She is an advisory board member for Integrative Biology.

Karmella Ann Haynes is a biomedical engineer and associate professor at the Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University. She researches how chromatin is used to control cell development in biological tissue.

<span class="mw-page-title-main">Christina Agapakis</span> American biologist

Christina Maria Agapakis is a synthetic biologist, science writer. She is the Creative Director of the biotechnology company Ginkgo Bioworks.

<span class="mw-page-title-main">China National GeneBank</span>

<i>VIPER</i> (rover) Planned NASA lunar rover

VIPER is a lunar rover developed by NASA, and currently planned to be delivered to the surface of the Moon in November 2024. The rover will be tasked with prospecting for lunar resources in permanently shadowed areas in the lunar south pole region, especially by mapping the distribution and concentration of water ice. The mission builds on a previous NASA rover concept called Resource Prospector, which was cancelled in 2018.

<span class="mw-page-title-main">Living medicine</span>

A living medicine is a type of biologic that consists of a living organism that is used to treat a disease. This usually takes the form of a cell or a virus that has been genetically engineered to possess therapeutic properties that is injected into a patient. Perhaps the oldest use of a living medicine is the use of leeches for bloodletting, though living medicines have advanced tremendously since that time.

Elizabeth Anne Specht is an American research scientist who is Vice President for Science and Technology at The Good Food Institute. She leads the development of a roadmap for the acceleration of alternative protein research. In 2022, Vox named her in one of their "Future Perfect 50".

References

  1. Jacobsen, Rowan. "John Cumbers is the connector of the gene-editing world". Quartz. Retrieved 2 September 2019.
  2. "Space entrepreneurs and dreamers gather in the desert to stargaze and make plans". The Seattle Times. 27 April 2019. Retrieved 18 April 2020.
  3. "Space entrepreneurs and dreamers gather in the desert to stargaze and make plans". The Seattle Times. 27 April 2019. Retrieved 18 April 2020.
  4. "Planetary Sustainabilty Initiative" (PDF). NASA. Retrieved 3 September 2019.
  5. Chapter 4 Fifteen Years of Innovation and Impact in COLLABORATIONS of CONSEQUENCE: NAKFI'S 15 YEARS IGNITING INNOVATION AT THE INTERSECTIONS OF DISCIPLINES. National Academies Press. 2018. ISBN   978-0-309-48365-0 . Retrieved 4 September 2019.
  6. "Ames-Industry Team uses the Rapid 'Ice' Method to Assess Synthetic Biology Applications to NASA's Asteroid Grand Challenge". NASA. Retrieved 4 September 2019.
  7. Check Hayden, Erika. "Tech investors bet on synthetic biology" (PDF). Nature. Retrieved 3 September 2019.
  8. Morton, Oliver. "The engineering of living organisms could soon start changing everything". The Economist. Retrieved 25 May 2019.
  9. LeMieux, Juliana. "One-Stop-Shop Genome Editing Product Launched by Inscripta". Genetic Engineering and Biotechnology News. Mary Ann Liebert. Retrieved 15 January 2020.
  10. "Codexis Spreading the Promise of Engineered Proteins at SynBioBeta Summit". Business Wire. Berkshire Hathaway. Retrieved 16 January 2020.
  11. "BetaSpace: The innovation ecosystem for our on-and off-planet future". SynBioBeta. Retrieved 25 June 2019.
  12. Dean, Sam. "As Coachella raged, the L.A. tech world made plans to live on Mars". Los Angeles Times. Retrieved 2 September 2019.
  13. Buhr, Sarah. "Data Collective and SynBioBeta founder John Cumbers launch a seed stage biotech fund". Tech Crunch. Retrieved 22 August 2019.
  14. Cumbers, John (2017). What's Your Bio-Strategy? How to Prepare your Business for Synthetic Biology. Pulp Bio Books. p. 190. ISBN   978-0999313619 . Retrieved 4 September 2019.
  15. Albert, Helen. "Here are our 10 favorite biotech books you should read this summer". Labiotech.eu. Retrieved 4 September 2019.
  16. Flatt, Thomas; Min, Kyung-Jin; D'Alterio, Cecilia; Villa Cuesta, Eugenia; Cumbers, John; Lehman, Ruth (23 April 2008). "Drosophila germ-line modulation of insulin signaling and lifespan". PNAS. 105 (17): 6368–6373. Bibcode:2008PNAS..105.6368F. doi: 10.1073/pnas.0709128105 . PMC   2359818 . PMID   18434551.
  17. Kelly, Jason; Rubin, Adam; Davis, Joseph; Ajo-Franklin, Caroline; Cumbers, John; Czar, Michael (20 March 2009). "Measuring the activity of BioBrick promoters using an in vivo reference standard". Journal of Biological Engineering. 3: 4. doi: 10.1186/1754-1611-3-4 . PMC   2683166 . PMID   19298678.
  18. Menezes, Amor; Cumbers, John; Hogan, John; Arkin, Adam (6 January 2006). "Towards synthetic biological approaches to resource utilization on space missions". Journal of the Royal Society Interface. 12 (102). doi:10.1098/rsif.2014.0715. PMC   4277073 . PMID   25376875.
  19. Montague, Michael; McArthur, George H; Cockell, Charles; Held, Jason; Marshall, William; Sherman, Louis (10 December 2012). "The Role of Synthetic Biology for In Situ Resource Utilization (ISRU)". Astrobiology. 12 (12): 1135–1142. Bibcode:2012AsBio..12.1135M. doi:10.1089/ast.2012.0829. PMID   23140229 . Retrieved 1 September 2019.
  20. Menezes, Amor; Montague, Michael; Cumbers, John; Hogan, John; Arkin, Adam (6 December 2015). "Grand challenges in space synthetic biology". Journal of the Royal Society Interface. 12 (113). doi:10.1098/rsif.2015.0803. PMC   4707852 . PMID   26631337.
  21. Horikawa, Daiki; Cumbers, John; Sakakibara, Iori; Rogoff, Dana; Leuko, Stefan; Harnato, Raechel (6 June 2013). "Analysis of DNA Repair and Protection in the Tardigrade Ramazzottius varieornatus and Hypsibius dujardini after Exposure to UVC Radiation". PLOS ONE. 8 (6): e64793. Bibcode:2013PLoSO...864793H. doi: 10.1371/journal.pone.0064793 . PMC   3675078 . PMID   23762256.
  22. Cahan, Bruce; Pittman, R Bruce; Cooper, Sarah; Cumbers, John (1 September 2018). "Space Commodities Futures Trading Exchange: Adapting Terrestrial Market Mechanisms to Grow a Sustainable Space Economy". New Space. 6 (3): 211–226. Bibcode:2018NewSp...6..211C. doi:10.1089/space.2017.0047 . Retrieved 4 September 2019.
  23. Cumbers, John. "Contributor Bio". Forbes. Retrieved 23 August 2019.
  24. Cumbers, John. "5 Reasons Jeff Bezos Should Bet Big On Synthetic Biology". Forbes. Retrieved 4 September 2019.
  25. "KECK FUTURES INITIATIVE AWARDS $1.25 MILLION FOR 13 RESEARCH PROJECTS". National Academies of Science, Engineering and Medicine. National Academies. Retrieved 12 January 2020.